- Poster presentation
- Open Access
Adverse events during anti-TNF therapy in 269 patients with juvenile idiopathic arthritis
© Tarkiainen et al; licensee BioMed Central Ltd. 2008
- Published: 15 September 2008
- Juvenile Idiopathic Arthritis
Patients with juvenile idiopathic arthritis (JIA), non-responsive to disease-modifying anti-rheumatic drugs (DMARDs) are treated with anti-TNF agents. The aim of this study was to evaluate the occurrence of adverse events (AEs) in these refractory patients.
In three tertiary centers patient charts were reviewed, and for each anti-TNF drug the severity and type of AEs were specified. Of 269 patients, 97% were on concomitant DMARDs at anti-TNF onset. Their mean age was 5.4 years (SD ± 3.8) at disease onset and 10.5 years (SD ± 3.9) at anti-TNF onset.
AEs and SAEs per patient-year during anti-TNF therapy
Infections were the most common AEs in patients with JIA receiving anti-TNF therapy, but the rate of serious infections seemed to be low.
This article is published under license to BioMed Central Ltd.